Galectin Therapeutics uses its knowledge of galectin proteins to study the effects of our proprietary compounds in diseases with clinical needs. Our compounds act as galectin inhibitors, binding to galectin proteins and disrupting their function, which has a beneficial effect on the disease states.
Our drug candidate in development (GR-MD-02, or belapectin) is a new chemical entity generated from naturally occurring carbohydrate polymers as starting material using proprietary chemistry. Currently in development, belapectin, a new chemical entity, is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, though it has greater binding affinity to galectin-3 than to galectin-1. Belapectin targets extracellular galectins. Click here to view our pipeline.
Learn about our development program and key data for belapectin.
Read about our intellectual property protection for GR-MD-02.
Currently in development, belapectin (GR-MD-02) is a new chemical entity and a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 (Miller 2009 Biochem J.pdf) and to galectin-3 (unpublished data), with greater binding affinity to galectin-3. Belapectin targets extracellular galectins.
Key features include:
Read about our intellectual property protection for belapectin (GR-MD-02).